Search
Enprofylline
go.drugbank.com/drugs/DB00824ApprovedWithdrawnEnprofylline is a derivative of theophylline which shares bronchodilator properties. … Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Synonyms: 3-n-propylxanthineFecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalFecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients … [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.
Equine Botulinum Neurotoxin A Immune FAB2
go.drugbank.com/drugs/DB13900ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients. … Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A.
Synonyms: Botulinum Neurotoxin A immune FAB2 (equine), BOTULINUM NEUROTOXIN A IMMUNE FAB2, EQUINEEverolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIn a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. … Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity. … Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]
Categories: Compounds used in a research, industrial, or household settingGuanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigational[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Cycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnIt is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.
Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidine